• admin@ataxiatelangiectasia.es
Ataxia Telangiectasia
  • Home
  • Bibliography
    • Authors
    • Cells and molecules
    • Clinical
    • Country
    • Diseases
    • Drugs
    • Experimental
    • Journals
    • Methods
    • Year
  • Resources
  • What is A-T?
  • News

Bibliography

  • Real-life Wrist Movement Patterns Capture Motor Impairment in Individuals with Ataxia-Telangiectasia
    Hits: 968
    • ataxia telangiectasia
    • United States of America
    • Cerebellum
    • biomarker
    • Gupta A
    • 2022
    • Thornton JK
    • wearable devices
     
    2022 Mar 16;1-11.
     doi: 10.1007/s12311-022-01385-5. Online ahead of print.

    Real-life Wrist Movement Patterns Capture Motor Impairment in Individuals with Ataxia-Telangiectasia

    Anoopum S Guptaagupta@mgh.harvard.edu.">1, Anna C Luddy2, Nergis C Khan23, Sara Reiling4, Jennifer Karlin Thornton4
    Affiliations 

    Affiliations

    • 1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge St, Boston, MA, USA. agupta@mgh.harvard.edu.
    • 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge St, Boston, MA, USA.
    • 3Stanford University School of Medicine, Stanford, CA, USA.
    • 4Ataxia Telangiectasia Children's Project, Coconut Creek, FL, USA.
      • PMID: 35294727
     
      • PMCID: PMC8926103
     
    • DOI: 10.1007/s12311-022-01385-5
    Free PMC article

    Abstract

    Sensitive motor outcome measures are needed to efficiently evaluate novel therapies for neurodegenerative diseases. Devices that can passively collect movement data in the home setting can provide continuous and ecologically valid measures of motor function. We tested the hypothesis that movement patterns extracted from continuous wrist accelerometer data capture motor impairment and disease progression in ataxia-telangiectasia. One week of continuous wrist accelerometer data were collected from 31 individuals with ataxia-telangiectasia and 27 controls aged 2-20 years old. Longitudinal wrist sensor data were collected in 14 ataxia-telangiectasia participants and 13 controls. A novel algorithm was developed to extract wrist submovements from the velocity time series. Wrist sensor features were compared with caregiver-reported motor function on the Caregiver Priorities and Child Health Index of Life with Disabilities survey and ataxia severity on the neurologist-performed Brief Ataxia Rating Scale. Submovements became smaller, slower, and less variable in ataxia-telangiectasia compared to controls. High-frequency oscillations in submovements were increased, and more variable and low-frequency oscillations were decreased and less variable in ataxia-telangiectasia. Wrist movement features correlated strongly with ataxia severity and caregiver-reported function, demonstrated high reliability, and showed significant progression over a 1-year interval. These results show that passive wrist sensor data produces interpretable and reliable measures that are sensitive to disease change, supporting their potential as ecologically valid motor biomarkers. The ability to obtain these measures from a low-cost sensor that is ubiquitous in smartwatches could help facilitate neurological care and participation in research regardless of geography and socioeconomic status.

    Keywords: Ataxia-telangiectasia; Biomarkers; Outcome measures; Wearable devices.

  • Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide
    Hits: 957
    • granulomas
    • United States of America
    • 2022
    • Pathogens
    • Nitazoxanide
    • Faisthalab R
    • Perelygina L
     
    . 2022 Mar 11;11(3):338.
     doi: 10.3390/pathogens11030338.

    Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide

    Raeesa Faisthalab1, Suganthi Suppiah1, Morna Dorsey2, Kathleen E Sullivan3, Joseph Icenogle1, Ludmila Perelygina1
    Affiliations 

    Affiliations

    • 1Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
    • 2Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
    • 3Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
      • PMID: 35335662
     
      • PMCID: PMC8955873
     
    • DOI: 10.3390/pathogens11030338
    Free PMC article

    Abstract

    A strong association between rubella virus (RuV) and chronic granulomas, in individuals with inborn errors of immunity, has been recently established. Both the RA27/3 vaccine and wild-type RuV strains were highly sensitive to a broad-spectrum antiviral drug, nitazoxanide (NTZ), in vitro. However, NTZ treatment, used as a salvage therapy, resulted in little or no improvements of RuV-associated cutaneous granulomas in patients. Here, we report investigations of possible causes of treatment failures in two ataxia-telangiectasia patients. Although a reduction in RuV RNA in skin lesions was detected by real-time RT-PCR, live immunodeficiency-related vaccine-derived rubella viruses (iVDRV) were recovered from granulomas, before and after the treatments. Tizoxanide, an active NTZ metabolite, inhibited replications of all iVDRVs in cultured A549 cells, but the 50% and 90% inhibitory concentrations were 10-40 times higher than those for the RA27/3 strain. There were no substantial differences in iVDRV sensitivities, neither before nor after treatments. Analysis of quasispecies in the E1 gene, a suspected NTZ target, showed no effect of NTZ treatments on quasispecies' complexity in lesions. Thus, failures of NTZ therapies were likely due to low sensitivities of iVDRVs to the drug, and not related to the emergence of resistance, following long-term NTZ treatments.

    Keywords: ataxia-telangiectasia; cutaneous granulomas; immunodeficiency-related vaccine-derived rubella viruses (iVDRV); nitazoxanide; quasispecies.

  • The investigated case of etiology of chylous pleural effusion: Ataxia-telangiectasia
    Hits: 873
    • Turkey
    • cases
    • 2022
    • Tuberk Toraks
    • Sak I
    • Çelik P
    • pleural effusion
    Case Reports
     
     
    . 2022 Mar;70(1):102-106.
     doi: 10.5578/tt.20229912.

    The investigated case of etiology of chylous pleural effusion: Ataxia-telangiectasia

    Işıl Sak1, Deniz Kızılırmak1, Yavuz Havlucu1, Zeynep Yılmaz1, Pınar Çelik1
    Affiliations 

    Affiliation

    • 1Department of Chest Diseases, Celal Bayar University Faculty of Medicine, Manisa, Turkey.
      • PMID: 35362310
     
    • DOI: 10.5578/tt.20229912
    Free article

    Abstract

    Ataxia-telangiectasia is an autosomal recessive, rare, neurodegenerative multisystem disorder characterized by ataxia-telangiectasia, cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, progressive respiratory failure associated with increased malignancy risk. Clinical diagnosis is made with ataxia-telangiectasia mutated (ATM) gene. Our case, who was diagnosed as ataxia-telangiectasia while investigating the etiology of chylous pleural effusion, is presented because of its rare occurrence.

  • Effectiveness of Person-Environment-Occupation Model on a Pediatric Neurodegenerative Disease: A Case Report of a Child with Ataxia-Telangiectasia
    Hits: 911
    • Iran
    • cases
    • 2022
    • Occup Ther Health Care
    • Joveini G
    • Hejazi-Shirmard M
    • occupational therapy
     
    . 2022 Apr 6;1-12.
     doi: 10.1080/07380577.2022.2059824. Online ahead of print.

    Effectiveness of Person-Environment-Occupation Model on a Pediatric Neurodegenerative Disease: A Case Report of a Child with Ataxia-Telangiectasia

    Ghodsiyeh Joveini1, Mohammad Malja2, Mahnaz Hejazi-Shirmard2
    Affiliations 

    Affiliations

    • 1Department of Occupational Therapy, School of Rehabilitation Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.
    • 2Department of Occupational Therapy, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
      • PMID: 35382675
     
    • DOI: 10.1080/07380577.2022.2059824

    Abstract

    Ataxia-telangiectasia is a rare neurodegenerative disorder characterized by progressive cerebellar ataxia, oculomotor apraxia, and choreoathetosis. Ataxia-telangiectasia is a devastating disease that negatively affects the participation of patients in daily occupations and consequently has adverse impacts on the quality of life of them and their families. This study aimed to investigate the effects of an occupational therapy intervention based on the Person-Environment-Occupation Model (PEO) on a 9-year old boy with ataxia-telangiectasia. Following a ten-session intervention, the client experienced significant improvement in occupational performance as well as participation in daily occupations as measured by Canadian Occupational Performance Measure (COPM) and the Pediatric Evaluation of Disability Inventory (PEDI), respectively.

    Keywords: Ataxia-telangiectasia; case report; occupational therapy; person-environment-occupation model.

  • Eye Movement Disorders in Movement Disorders
    Hits: 1144
    • United Kingdom
    • United States of America
    • Movement disorders
    • eye movements
    • Mov Disord Clin Pract
    • 2022
    • New Zealand
    • Kassaetis P
    • Hallett M
    Review
     
     
    . 2022 Feb 16;9(3):284-295.
     doi: 10.1002/mdc3.13413. eCollection 2022 Apr.

    Eye Movement Disorders in Movement Disorders

    Panagiotis Kassavetis12, Diego Kaski3, Tim Anderson45, Mark Hallett1
    Affiliations 

    Affiliations

    • 1National Institute of Neurological Disorders and Stroke, National Institutes of Health Bethesda Maryland USA.
    • 2Department of Neurology University of Utah Salt Lake City Utah USA.
    • 3Centre for Vestibular and Behavioural Neurosciences, Department of Clinical and Movement Neurosciences University College London, Institute of Neurology London UK.
    • 4New Zealand Brain Research Institute Christchurch New Zealand.
    • 5Department of Medicine University of Otago Christchurch New Zealand.
      • PMID: 35402641
     
      • PMCID: PMC8974874 (available on 2023-02-16)
     
    • DOI: 10.1002/mdc3.13413

    Abstract

    Oculomotor assessment is an essential element of the neurological clinical examination and is particularly important when evaluating patients with movements disorders. Most of the brain is involved in oculomotor control, and thus many neurological conditions present with oculomotor abnormalities. Each of the different classes of eye movements and their features can provide important information that can facilitate differential diagnosis. This educational review presents a clinical approach to eye movement abnormalities that are commonly seen in parkinsonism, ataxia, dystonia, myoclonus, tremor, and chorea. In parkinsonism, subtle signs such as prominent square wave jerks, impaired vertical optokinetic nystagmus, and/or the "round the houses" sign suggest early progressive supranuclear gaze palsy before vertical gaze is restricted. In ataxia, nystagmus is common, but other findings such as oculomotor apraxia, supranuclear gaze palsy, impaired fixation, or saccadic pursuit can contribute to diagnoses such as ataxia with oculomotor apraxia, Niemann-Pick type C, or ataxia telangiectasia. Opsoclonus myoclonus and oculopalatal myoclonus present with characteristic phenomenology and are usually easy to identify. The oculomotor exam is usually unremarkable in isolated dystonia, but oculogyric crisis is a medical emergency and should be recognized and treated in a timely manner. Gaze impersistence in a patient with chorea suggests Huntington's disease, but in a patient with dystonia or tremor, Wilson's disease is more likely. Finally, functional eye movements can reinforce the clinical impression of a functional movement disorder.

    Keywords: eye; movement disorders; oculomotor; pursuit; saccades.

  • Ataxia-telangiectasia syndrome
    Hits: 866
    • ataxia telangiectasia
    • Portugal
    • 2022
    • Fortuna J
    • Pires P
     
    . 2022 Mar 23;S1875-9572(22)00057-2.
     doi: 10.1016/j.pedneo.2022.01.004. Online ahead of print.

    Ataxia-telangiectasia syndrome

    Joana Fortunafortuna_joana@hotmail.com.">1, Ana Luisa Rodrigues2, Paula Pires3
    Affiliations 

    Affiliations

    • 1Pediatrics Department, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal. Electronic address: fortuna_joana@hotmail.com.
    • 2Pediatrics Department, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal.
    • 3Neurology Department, Hospital de Santo Espírito da Ilha Terceira, Angra do Heroísmo, Portugal.
      • PMID: 35431147
     
    • DOI: 10.1016/j.pedneo.2022.01.004
    No abstract available
  • Metabolic Stress and Mitochondrial Dysfunction in Ataxia-Telangiectasia
    Hits: 979
    • Lavin MF
    • Australia
    • Yeo AJ
    • Gatei M
    • mitochondrial dysfunction
    • Subramanian GN
    • Coman D
    • 2022
    • Antioxidants (Basel)

    Metabolic Stress and Mitochondrial Dysfunction in Ataxia-Telangiectasia

    Goutham Narayanan Subramanian1, Abrey Jie Yeo1, Magtouf Hnaidi Gatei1, David John Coman23, Martin Francis Lavin1
    Affiliations 

    Affiliations

    • 1University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, QLD 4029, Australia.
    • 2Queensland Children's Hospital, Brisbane, QLD 4101, Australia.
    • 3Faculty of Medicine, University of Queensland, Brisbane, QLD 4006, Australia.
      • PMID: 35453338
     
      • PMCID: PMC9032508
     
    • DOI: 10.3390/antiox11040653
    Free PMC article

    Abstract

    The ataxia-telangiectasia mutated (ATM) protein kinase is, as the name implies, mutated in the human genetic disorder ataxia-telangiectasia (A-T). This protein has its "finger in many pies", being responsible for the phosphorylation of many thousands of proteins in different signaling pathways in its role in protecting the cell against a variety of different forms of stress that threaten to perturb cellular homeostasis. The classical role of ATM is the protection against DNA damage, but it is evident that it also plays a key role in maintaining cell homeostasis in the face of oxidative and other forms of non-DNA damaging stress. The presence of ATM is not only in the nucleus to cope with damage to DNA, but also in association with other organelles in the cytoplasm, which suggests a greater protective role. This review attempts to address this greater role of ATM in protecting the cell against both external and endogenous damage.

    Keywords: anaplerosis; ataxia-telangiectasia; ataxia-telangiectasia mutated protein kinase; metabolic stress; mitochondrial dysfunction.

  • Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry
    Hits: 935
    • Spain
    • 2011
    • hereditary cancer syndromes
    • B Graña
    • hereditary breast cancer
    • J Brunet
    Comparative Study
     
     
    . 2011 Jul;128(2):573-9.
     doi: 10.1007/s10549-011-1462-x. Epub 2011 Mar 29.

    Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry

    B Grañabgrana@vhebron.net">1, L Fachal, E Darder, J Balmaña, T Ramón Y Cajal, I Blanco, A Torres, C Lázaro, O Diez, C Alonso, M Santamariña, A Velasco, A Teulé, A Lasa, A Blanco, A Izquierdo, J Borràs, S Gutiérrez-Enríquez, A Vega, J Brunet
    Affiliations 

    Affiliation

    • 1High Risk and Cancer Prevention Unit, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain. bgrana@vhebron.net
      • PMID: 21445571
     
    • DOI: 10.1007/s10549-011-1462-x

    Abstract

    Biallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-telangiectasia (A-T). Female relatives of A-T patients have a two-fold higher risk of developing breast cancer (BC) compared with the general population. ATM mutation carrier identification is laborious and expensive, therefore, a more rapid and directed strategy for ATM mutation profiling is needed. We designed a case-control study to determine the prevalence of 32 known ATM mutations causing A-T in Spanish population in 323 BRCA1/BRCA2 negative hereditary breast cancer (HBC) cases and 625 matched Spanish controls. For the detection of the 32 ATM mutations we used the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry technique. We identified one patient carrier of the c.8264_8268delATAAG ATM mutation. This mutation was not found in the 625 controls. These results suggest a low frequency of these 32 A-T causing mutations in the HBC cases in our population. Further case-control studies analyzing the entire coding and flanking sequences of the ATM gene are warranted in Spanish BC patients to know its implication in BC predisposition.

  • Mild Neurological Phenotype Associated with Hypomorphic Variants in the Ataxia-Telangiectasia Mutated Gene
    Hits: 1037
    • Italy
    • ATM kinase
    • Leuzzi V
    • Piane M
    • Caputi C
    • Variant ataxia-telangiectasia
    • Federici G
    • Soddu S
    • 2022
    • Travaglini L
    • Bertini E
    • Zanni G
    • Mild Neurological Phenotype
    Case Reports
     
     
    2022 Dec 10;10(1):124-129.
     doi: 10.1002/mdc3.13618. eCollection 2023 Jan.

    Mild Neurological Phenotype Associated with Hypomorphic Variants in the Ataxia-Telangiectasia Mutated Gene

    Caterina Caputi1, Giulia Federici2, Silvia Soddu2, Lorena Travaglini3, Maria Piane4, Enrico Bertini3, Ginevra Zanni3, Vincenzo Leuzzi1
    Affiliations 

    Affiliations

    • 1Department of Human Neuroscience Sapienza University Rome Italy.
    • 2Unit of Cellular Networks and Molecular Therapeutic Targets Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute Rome Italy.
    • 3Unit of Neuromuscular and Neurodegenerative Diseases Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Bambino Gesù Children's Hospital Rome Italy.
    • 4Department of Clinical and Molecular Medicine Sapienza University Rome Italy.
      • PMID: 36704080
     
      • PMCID: PMC9847291 (available on 2023-12-10)
     
    • DOI: 10.1002/mdc3.13618

    Abstract

    Background: Ataxia-telangiectasia (A-T) is a progressive multisystemic neurodegenerative disease. The phenotypic spectrum includes conditions (variant A-T) with mild, late-onset, and atypical clinical presentations characterized by the prevalence of dyskinetic rather than ataxic features.

    Cases: We describe the clinical presentations of 3 siblings with early-onset truncal ataxia without obvious neurological deterioration or biological markers of classic A-T phenotype. We performed functional and genetic evaluation of 3 siblings with very mild neurological phenotype. Genetic evaluation with a next-generation sequencing panel for genes causative of cerebellar ataxia detected 2 known ATM gene variants, missense c.9023G>A p.(Arg3008His), and leaky splicing c.1066-6T>G variants. Functional studies showed mildly reduced ATM expression and residual kinase activity in the probands compared with healthy controls.

    Conclusions: These results suggest the importance of investigating ATM variants even in the presence of clinical and biological atypical cases to ensure specific therapeutic regimens and oncological surveillance in these patients.

    Keywords: functional studies; kinase activity; mild phenotype; p53‐MCL; variant ataxia‐telangiectasia.

    © 2022 International Parkinson and Movement Disorder Society.

  • Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia
    Hits: 220
    • Schubert R
    • Zielen S
    • Germany
    • Italy
    • The Netherlands
    • Poland
    • Spain
    • France
    • Turkey
    • IgA deficiency
    • Egypt
    • J Clin Immunol
    • Santos Pérez JL
    • 2021
    • Soler-Palacin P
    • mortality
    • Ukraine
    • Austria
    • Rodriguez-Gallego C
    • González-Granado LI
    Clinical Trial
     
     
    . 2021 Nov;41(8):1878-1892.
     doi: 10.1007/s10875-021-01090-8. Epub 2021 Sep 3.

    Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia

    Stefan Zielen1, Ruth Pia DueckerRuthPia.Duecker@kgu.de.">2, Sandra Woelke1, Helena Donath1, Sharhzad Bakhtiar3, Aileen Buecker1, Hermann Kreyenberg3, Sabine Huenecke3, Peter Bader3, Nizar Mahlaoui4, Stephan Ehl5, Sabine M El-Helou567, Barbara Pietrucha8, Alessandro Plebani9, Michiel van der Flier10, Koen van Aerde11, Sara S Kilic12, Shereen M Reda13, Larysa Kostyuchenko14, Elizabeth McDermott15, Nermeen Galal16, Claudio Pignata17, Juan Luis Santos Pérez18, Hans-Juergen Laws19, Tim Niehues20, Necil Kutukculer21, Markus G Seidel22, Laura Marques23, Peter Ciznar24, John David M Edgar25, Pere Soler-Palacín26, Horst von Bernuth272829, Renate Krueger27, Isabelle Meyts30, Ulrich Baumann31, Maria Kanariou32, Bodo Grimbacher5633, Fabian Hauck34, Dagmar Graf35, Luis Ignacio Gonzalez Granado36, Seraina Prader37, Ismail Reisli38, Mary Slatter39, Carlos Rodríguez-Gallego40, Peter D Arkwright41, Claire Bethune42, Elena Deripapa43, Svetlana O Sharapova44, Kai Lehmberg45, E Graham Davies46, Catharina Schuetz47, Gerhard Kindle548, Ralf Schubert1
    Affiliations 
      • PMID: 34477998
     
      • PMCID: PMC8604875
     
    • DOI: 10.1007/s10875-021-01090-8
    Free PMC article

    Abstract

    Patients with ataxia-telangiectasia (A-T) suffer from progressive cerebellar ataxia, immunodeficiency, respiratory failure, and cancer susceptibility. From a clinical point of view, A-T patients with IgA deficiency show more symptoms and may have a poorer prognosis. In this study, we analyzed mortality and immunity data of 659 A-T patients with regard to IgA deficiency collected from the European Society for Immunodeficiencies (ESID) registry and from 66 patients with classical A-T who attended at the Frankfurt Goethe-University between 2012 and 2018. We studied peripheral B- and T-cell subsets and T-cell repertoire of the Frankfurt cohort and survival rates of all A-T patients in the ESID registry. Patients with A-T have significant alterations in their lymphocyte phenotypes. All subsets (CD3, CD4, CD8, CD19, CD4/CD45RA, and CD8/CD45RA) were significantly diminished compared to standard values. Patients with IgA deficiency (n = 35) had significantly lower lymphocyte counts compared to A-T patients without IgA deficiency (n = 31) due to a further decrease of naïve CD4 T-cells, central memory CD4 cells, and regulatory T-cells. Although both patient groups showed affected TCR-ß repertoires compared to controls, no differences could be detected between patients with and without IgA deficiency. Overall survival of patients with IgA deficiency was significantly diminished. For the first time, our data show that patients with IgA deficiency have significantly lower lymphocyte counts and subsets, which are accompanied with reduced survival, compared to A-T patients without IgA deficiency. IgA, a simple surrogate marker, is indicating the poorest prognosis for classical A-T patients. Both non-interventional clinical trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia-telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk and liver disease in patients with ataxia-telangiectasia; NCT03357978).

    Keywords: Ataxia-telangiectasia; IgA deficiency; Immunodeficiency; Immunoglobulins; Lymphopenia; Mortality.

  • Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia
    Hits: 88
    • Schubert R
    • Germany
    • Switzerland
    • Reichenbach J
    • gene therapy
    • Hirch T
    • Brander N
    • Schenk F
    • Pöllman SJ
    • Modlich U
    • 2023
     
    . 2023 Nov 8;13(1):19386.
     doi: 10.1038/s41598-023-46332-4.

    Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia

    Tanja Hirch1, Nadine Brander1, Franziska Schenk1, Simon J Pöllmann12, Janine Reichenbach234, Ralf Schubert5, Ute Modlichute.modlich@irem.uzh.ch.">6ute.modlich@irem.uzh.ch.">7
    Affiliations 

    Affiliations

    • 1Division of Veterinary Medicine, RG Gene Modification in Stem Cells, Paul-Ehrlich-Institute, Langen, Germany.
    • 2Department of Gene and Cell Therapy, Institute for Regenerative Medicine - IREM, University of Zurich, Schlieren, Switzerland.
    • 3Deptartment of Somatic Gene Therapy, University Children's Hospital Zurich, Zurich, Switzerland.
    • 4Competence Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland.
    • 5Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
    • 6Division of Veterinary Medicine, RG Gene Modification in Stem Cells, Paul-Ehrlich-Institute, Langen, Germany. ute.modlich@irem.uzh.ch.
    • 7Department of Gene and Cell Therapy, Institute for Regenerative Medicine - IREM, University of Zurich, Schlieren, Switzerland. ute.modlich@irem.uzh.ch.
      • PMID: 37938627
     
      • PMCID: PMC10632516
     
    • DOI: 10.1038/s41598-023-46332-4
    Free PMC article

    Abstract

    Ataxia telangiectasia is a monogenetic disorder caused by mutations in the ATM gene. Its encoded protein kinase ATM plays a fundamental role in DNA repair of double strand breaks (DSBs). Impaired function of this kinase leads to a multisystemic disorder including immunodeficiency, progressive cerebellar degeneration, radiation sensitivity, dilated blood vessels, premature aging and a predisposition to cancer. Since allogenic hematopoietic stem cell (HSC) transplantation improved disease outcome, gene therapy based on autologous HSCs is an alternative promising concept. However, due to the large cDNA of ATM (9.2 kb), efficient packaging of retroviral particles and sufficient transduction of HSCs remains challenging.We generated lentiviral, gammaretroviral and foamy viral vectors with a GFP.F2A.Atm fusion or a GFP transgene and systematically compared transduction efficiencies. Vector titers dropped with increasing transgene size, but despite their described limited packaging capacity, we were able to produce lentiviral and gammaretroviral particles. The reduction in titers could not be explained by impaired packaging of the viral genomes, but the main differences occurred after transduction. Finally, after transduction of Atm-deficient (ATM-KO) murine fibroblasts with the lentiviral vector expressing Atm, we could show the expression of ATM protein which phosphorylated its downstream substrates (pKap1 and p-p53).

  • Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia
    Hits: 53
    • Mov Disord
    • Norway
    • Nicotinamide Riboside
    • 2023
     
    . 2023 Oct 29.
     doi: 10.1002/mds.29645. Online ahead of print.

     

    Rebecca Presterud1, Wei Hai Deng23, Anna Berit Wennerström4, Trudy Burgers5, Bharat Gajera6, Kirsten Mattsson5, Agnes Solberg5, Evandro F Fang147, Anni I Nieminen6, Asbjørg Stray-Pedersen58, Hilde Nilsen1479
    Affiliations 
      • PMID: 37899683
     
    • DOI: 10.1002/mds.29645

    Abstract

    Background: Supplementation of nicotinamide riboside (NR) ameliorates neuropathology in animal models of ataxia telangiectasia (A-T). In humans, short-term NR supplementation showed benefits in neurological outcome.

    Objectives: The study aimed to investigate the safety and benefits of long-term NR supplementation in individuals with A-T.

    Methods: A single-arm, open-label clinical trial was performed in individuals with A-T, receiving NR over a period of 2 years. Biomarkers and clinical examinations were used to assess safety parameters. Standardized and validated neuromotor tests were used to monitor changes in neurological symptoms. Using generalized mixed models, test results were compared to expected disease progression based on historical data.

    Results: NAD+ concentrations increased rapidly in peripheral blood and stabilized at a higher level than baseline. NR supplementation was well tolerated for most participants. The total scores in the neuromotor test panels, as evaluated at the 18-month time point, improved for all but one participant, primarily driven by improvements in coordination subscores and eye movements. A comparison with historical data revealed that the progression of certain neuromotor symptoms was slower than anticipated.

    Conclusions: Long-term use of NR appears to be safe and well tolerated, and it improves motor coordination and eye movements in patients with A-T of all ages. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

    Keywords: ataxia telangiectasia; niagen; nicotinamide riboside.

    © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

    PubMed Disclaimer

    References

      1. Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988;336(6199):577-580.
      1. McGrath-Morrow SA, Rothblum-Oviatt CC, Wright J, Schlechter H, Lefton-Greif MA, Natale VA, et al. Multidisciplinary Management of Ataxia Telangiectasia: current perspectives. J Multidiscip Healthc 2021;14:1637-1644.
      1. Aguado J, Gómez-Inclán C, Leeson HC, Lavin MF, Shiloh Y, Wolvetang EJ. The hallmarks of aging in ataxia-telangiectasia. Ageing Res Rev 2022;79:101653.
      1. Petley E, Yule A, Alexander S, Ojha S, Whitehouse WP. The natural history of ataxia-telangiectasia (A-T): a systematic review. PloS One 2022;17(3):e0264177.
      1. Kim ST, Lim DS, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 1999;274(53):37538-37543.
  • Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial
    Hits: 1215
    • India
    • Eur J Paediatr Neurol
    • Iran
    • Clinical trial
    • N-acetyl-leucine
    • 2024
    Randomized Controlled Trial
     
     
    . 2024 May:50:57-63.
     doi: 10.1016/j.ejpn.2024.04.009. Epub 2024 Apr 22.

    Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial

    Mehran Beyraghi-Tousi1, Amirhosein Sahebkar2, Mahsa Houra3, Pooria Sarvghadi4, Tannaz Jamialahmadi5, Reza Bagheri6, Shima Tavallaie7, Eric Gumpricht8, Maryam Saberi-Karimiansaberikm@mums.ac.ir.">9
    Affiliations 
      • PMID: 38669738
     
    • DOI: 10.1016/j.ejpn.2024.04.009

    Abstract

    Background: Ataxia telangiectasia (AT) is an autosomal recessive multisystem disorder. Most patients have progressive cerebellar ataxia, oculocutaneous telangiectasia, frequent pulmonary infection, and an increased risk of malignancies. Although N-acetyl-dl-leucine (ADLL) has shown some efficacy in patients with AT, its more pharmacologically active enantiomer, N-acetyl-l-leucine (NALL), has just recently been investigated in ataxic individuals. The current study assessed the efficacy of NALL in patients with AT.

    Methods: This 2 × 2 crossover, double-blind, randomized clinical trial was conducted on 20 patients with AT. After excluding four patients, 16 subjects (eight females, eight males; mean age 9.8 ± 3.5 years) with a definitive genetic diagnosis of AT were randomly assigned to one of two study groups, with one group receiving 1-4 g/day NALL or a placebo for six weeks. Subjects then had a 4-week washout before crossing over to the other treatment for an additional six weeks. The Spinocerebellar Ataxia Functional Index (SCAFI) and the Scale for Assessment and Rating of Ataxia (SARA) score assessed patients' motor function. Quality of life (QOL) was evaluated by a specialist using the PedsQL questionnaire. Fasting blood samples were taken from all subjects before and after each intervention to determine potential side effects.

    Results: Although patients' nausea and constipation were improved, the results failed to reveal any significant benefits of NALL treatment on ataxia symptoms. NALL treatment had no significant effects on SARA, SCAFI-9HPT (9-hole peg test) nondominant, SCAFI-9HPT dominant, or SCAFI-8WMT (8 m walking time) (p > 0.05). Our patient's Physical Health score in Child self-report and Parent proxy-report did not significantly change in the treatment group compared to the placebo (p > 0.05). Furthermore, there were no significant changes in energy and macronutrient intake after NALL treatment. None of the volunteers reported serious or moderate side effects.

    Conclusions: To the best of our knowledge, this was the first placebo-controlled, randomized clinical trial exploring NALL's potential effects for treating AT. Despite improvements in some symptomss, NALL intervention failed to improve motor function significantly. However, patients' nausea and constipation were improved by NALL, which can be a relevant benefit clinically.

    Keywords: ATM; Ataxia telangiectasia; Clinical trial; N-acetyl-leucine.

  • The Care and Management of Children and Young People with Ataxia Telangiectasia Provided by Nurses and Allied Health Professionals: a Scoping Review
    Hits: 1013
    • United Kingdom
    • rehabilitation
    • 2023
    • Child care
    • Multidisciplinary management
    Review
     
     
    . 2024 Apr;23(2):722-756.
     doi: 10.1007/s12311-023-01555-z. Epub 2023 Apr 29.

    The Care and Management of Children and Young People with Ataxia Telangiectasia Provided by Nurses and Allied Health Professionals: a Scoping Review

    Munira Khan1, Elizabeth Cassidy2, Tracey Parkin1, Amanda Wallace1, Bernie Carter3, Joanne Paton1, Kathryn Donohue1, Susan Mitchell1, Gemma Quin1, Nicola McNarry4, Helen Hartley5, Hannah Bailey6, William Whitehouse4, Rachel Medd7, Asma Zahidi1, Miriam McMullan1, Lisa Bunnlisa.bunn@plymouth.ac.uk.">8
    Affiliations 
      • PMID: 37119406
     
      • PMCID: PMC10148630
     
    • DOI: 10.1007/s12311-023-01555-z

    Abstract

    Ataxia telangiectasia (A-T) is a rare, multisystem progressive condition that typically presents in early childhood. In the absence of cure, people with A-T require coordinated multidisciplinary care to manage their complex array of needs and to minimize the disease burden. Although symptom management has proven benefits for this population, including improved quality of life and reduced complications, there is a need for guidance specific to the nursing and allied healthcare teams who provide care within the community. A scoping review, adopting the Joanna Briggs Institute methodology, was undertaken. It aimed to identify and map the available expertise from nursing and allied healthcare and management of children and young people with A-T ≤ 18 years of age. A rigorous search strategy was employed which generated a total of 21,118 sources of evidence, of which 50 were selected for review following screening by experts. A range of interventions were identified that reported a positive impact on A-T-related impairments, together with quality of life, indicating that outcomes can be improved for this population. Most notable interventions specific to A-T include therapeutic exercise, inspiratory muscle training, and early nutritional assessment and intervention. Further research will be required to determine the full potential of the identified interventions, including translatability to the A-T setting for evidence related to other forms of ataxia. Large gaps exist in the nursing and allied health evidence-base, highlighting a need for robust research that includes children and young people with A-T and their families to better inform and optimize management strategies.

    Keywords: Ataxia telangiectasia; Cerebellar ataxia; Child care; Community health services; Multidisciplinary management; Rehabilitation.

  • A-T neurodegeneration and DNA damage-induced transcriptional stress
    Hits: 909
    • United States of America
    • Neurodegeneration
    • DNA damage
    • Inflammation
    • 2024
    Review
     
     
    . 2024 Mar:135:103647.
     doi: 10.1016/j.dnarep.2024.103647. Epub 2024 Feb 15.

    A-T neurodegeneration and DNA damage-induced transcriptional stress

    Tanya T Paulltpaull@utexas.edu.">1, Phillip R Woolley2
    Affiliations 
      • PMID: 38377644
     
    • DOI: 10.1016/j.dnarep.2024.103647

    Abstract

    Loss of the ATM protein kinase in humans results in Ataxia-telangiectasia, a disorder characterized by childhood-onset neurodegeneration of the cerebellum as well as cancer predisposition and immunodeficiency. Although many aspects of ATM function are well-understood, the mechanistic basis of the progressive cerebellar ataxia that occurs in patients is not. Here we review recent progress related to the role of ATM in neurons and the cerebellum that comes from many sources: animal models, post-mortem brain tissue samples, and human neurons in culture. These observations have revealed new insights into the consequences of ATM loss on DNA damage, gene expression, and immune signaling in the brain. Many results point to the importance of reactive oxygen species as well as single-strand DNA breaks in the progression of molecular events leading to neuronal dysfunction. In addition, innate immunity signaling pathways appear to play a critical role in ATM functions in microglia, responding to various forms of nucleic acid sensors and regulating survival of neurons and other cell types. Overall, the results lead to an updated view of transcriptional stress and DNA damage resulting from ATM loss that results in changes in gene expression as well as neuroinflammation that contribute to the cerebellar neurodegeneration observed in patients.

    Keywords: Ataxia-telangiectasia; DNA damage; Inflammation; Neurodegeneration.

  • Ataxia Telangiectasia in a Patient with Breast Cancer: A Case Report
    Hits: 870
    • Japan
    • breast cancer
    • cases
    • 2023
    Mari Mizuno300012@cc.u-tokai.ac.jp.">1, Yuko Ohnuki, Ai Unzaki, Mizuho Suzuki, Kei Takeshita, Saori Takahashi, Hikaru Kiyohara, Saeko Nakagawa, Rie Ishida, Kozue Yokoyama, Mayako Terao, Takuho Okamura, Toru Hanamura, Naoki Niikura
    Affiliations 
    • PMID: 37635070
    Free article

    Abstract

    Ataxia telangiectasia (AT) is a rare autosomal recessive disorder caused by the pathological variants of the ATM gene. Owing to i ts r arity a nd n ature, complications of AT, such a s malignant tumors, a re often difficult to manage with standard imaging studies and treatments, and there are no established management strategies. We report the case of a woman who had AT in childhood and developed breast cancer in her 20s; the disease was successfully managed by the decision-making of multidisciplinary physicians professionals with ethics support. She was immunocompromised, ataxic, and mentally impaired. The patient's mother noticed a tumor in her right breast and subsequently brought her to our department. Although preoperative testing and surgical procedures were limited as AT is extremely radiosensitive, the patient was diagnosed with cT2N0M0 breast cancer and underwent right mastectomy and axillary lymph node sampling. The final diagnosis was pT2N0M0 pStage IIA mucinous carcinoma, and immunohistochemistry of the tumor specimen was estrogen receptor-positive, progesterone receptor-positive, and HER2-negative. Tamoxifen was administered as postoperative adjuvant therapy, and the patient has survived to date without recurrence. Here, we report our experience with breast cancer treatment for AT, along with a review of the literature.

  • Cross-talk between DNA damage response and the central carbon metabolic network underlies selective vulnerability of Purkinje neurons in ataxia-telangiectasia
    Hits: 977
    • United States of America
    • Hong Kong
    • DNA damage
    • 2023
    • fuel metabolism
    • J Neurochem
    Review
     
     
    . 2023 Aug;166(4):654-677.
     doi: 10.1111/jnc.15881. Epub 2023 Jun 15.

    Cross-talk between DNA damage response and the central carbon metabolic network underlies selective vulnerability of Purkinje neurons in ataxia-telangiectasia

    Jacquelyne Ka-Li Sun1, Genper Chi-Ngai Wong1, Kim Hei-Man Chow123
    Affiliations 
      • PMID: 37319113
     
    • DOI: 10.1111/jnc.15881

    Abstract

    Cerebellar ataxia is often the first and irreversible outcome in the disease of ataxia-telangiectasia (A-T), as a consequence of selective cerebellar Purkinje neuronal degeneration. A-T is an autosomal recessive disorder resulting from the loss-of-function mutations of the ataxia-telangiectasia-mutated ATM gene. Over years of research, it now becomes clear that functional ATM-a serine/threonine kinase protein product of the ATM gene-plays critical roles in regulating both cellular DNA damage response and central carbon metabolic network in multiple subcellular locations. The key question arises is how cerebellar Purkinje neurons become selectively vulnerable when all other cell types in the brain are suffering from the very same defects in ATM function. This review intended to comprehensively elaborate the unexpected linkages between these two seemingly independent cellular functions and the regulatory roles of ATM involved, their integrated impacts on both physical and functional properties, hence the introduction of selective vulnerability to Purkinje neurons in the disease will be addressed.

    Keywords: DNA damage response; ataxia-telangiectasia; central carbon metabolism; fuel metabolism.

  • Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome
    Hits: 1006
    • United States of America
    • Clinical trial
    • biomarker
    • 2023
    • genetic intervention
    • Expert Opin Investig Drugs
    Review
     
     
    . 2023 Jul-Dec;32(8):693-704.
     doi: 10.1080/13543784.2023.2249399. Epub 2023 Aug 28.

    Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome

    Katrina Kuhn1, Howard M Lederman2, Sharon A McGrath-Morrow3
    Affiliations 
      • PMID: 37622329
     
      • PMCID: PMC10530584 (available on 2024-08-28)
     
    • DOI: 10.1080/13543784.2023.2249399
     

    Abstract

    Introduction: Ataxia telangiectasia (A-T) is a life-limiting autosomal recessive disease characterized by cerebellar degeneration, ocular telangiectasias, and sinopulmonary disease. Since there is no cure for A-T, the standard of care is primarily supportive.

    Areas covered: We review clinical trials available in PubMed from 1990 to 2023 focused on lessening A-T disease burden. These approaches include genetic interventions, such as antisense oligonucleotides, designed to ameliorate disease progression in patients with select mutations. These approaches also include pharmacologic treatments that target oxidative stress, inflammation, and mitochondrial exhaustion, to attenuate neurological progression in A-T. Finally, we discuss the use of biological immunotherapies for the treatment of malignancies and granulomatous disease, along with other supportive therapies being used for the treatment of pulmonary disease and metabolic syndrome.

    Expert opinion: Barriers to successful genetic and pharmacologic interventions in A-T include the need for personalized treatment approaches based on patient-specific ATM mutations and phenotypes, lack of an animal model for the neurologic phenotype, and extreme rarity of disease making large-scale randomized trials difficult to perform. Ongoing efforts are needed to diagnose patients earlier, discover more effective therapies, and include more individuals in clinical trials, with the goal to lessen disease burden and to find a cure for patients with A-T.

    Keywords: ATM; Ataxia telangiectasia (A-T); biomarker; clinical trial; genetic intervention.

  • The hallmarks of aging in Ataxia-Telangiectasia
    Hits: 1058
    • Senescence
    • Australia
    • oxidative stress
    • mitochondrial dysfunction
    • DNA damage
    • 2022
    • aging
    Review
     
     
    . 2022 Aug:79:101653.
     doi: 10.1016/j.arr.2022.101653. Epub 2022 May 26.

    The hallmarks of aging in Ataxia-Telangiectasia

    Julio Aguadoj.aguadoperez@uq.edu.au.">1, Cecilia Gómez-Inclán2, Hannah C Leeson2, Martin F Lavin3, Yosef Shiloh4, Ernst J Wolvetange.wolvetang@uq.edu.au.">5
    Affiliations 

    Affiliations

    • 1Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland 4072, Australia. Electronic address: j.aguadoperez@uq.edu.au.
    • 2Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland 4072, Australia.
    • 3University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Brisbane, Australia.
    • 4The David and Inez Myers Laboratory of Cancer Genetics, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University School of Medicine, Tel Aviv, Israel.
    • 5Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland 4072, Australia. Electronic address: e.wolvetang@uq.edu.au.
      • PMID: 35644374
     
    • DOI: 10.1016/j.arr.2022.101653

    Abstract

    Ataxia-telangiectasia (A-T) is caused by absence of the catalytic activity of ATM, a protein kinase that plays a central role in the DNA damage response, many branches of cellular metabolism, redox and mitochondrial homeostasis, and cell cycle regulation. A-T is a complex disorder characterized mainly by progressive cerebellar degeneration, immunodeficiency, radiation sensitivity, genome instability, and predisposition to cancer. It is increasingly recognized that the premature aging component of A-T is an important driver of this disease, and A-T is therefore an attractive model to study the aging process. This review outlines the current state of knowledge pertaining to the molecular and cellular signatures of aging in A-T and proposes how these new insights can guide novel therapeutic approaches for A-T.

    Keywords: ATM; Aging; Ataxia-telangiectasia; Cellular senescence; DNA damage response; Mitochondrial dysfunction; Oxidative stress.

  • Neurocognitive Impairment in Patients With Ataxia Telangiectasia and Their Unaffected Parents: Is It Similar?
    Hits: 854
    • Turkey
    • Cerebellum
    • Pediatr Neurol
    • Neuropsychology
     
    . 2024 Jul:156:85-90.
     doi: 10.1016/j.pediatrneurol.2024.04.010. Epub 2024 Apr 21.

    Neurocognitive Impairment in Patients With Ataxia Telangiectasia and Their Unaffected Parents: Is It Similar?

    Emel Uyaruyaremel@yahoo.com.">1, Hacer Akturk2, Sevil Usanmaz3, Ayca Kiykim4, Ali Evren Tufan5, Hande Alibas6, Omer Aydiner7, Ayper Somer8, Ahmet Ozen4, Safa Baris4, Elif Karakoc-Aydiner4
    Affiliations 
      • PMID: 38733859
     
    • DOI: 10.1016/j.pediatrneurol.2024.04.010

    Abstract

    Background: Ataxia telangiectasia (AT) is a genetic multisystemic disorder affecting the nervous system. Data on neurocognitive functioning in AT are limited and focused on patients at various stages of disease. Because of the genetic nature of the disorder, parents of patients may also display subtle neurological problems. This study aimed to evaluate neurocognitive functioning in patients with AT and their unaffected parents.

    Methods: The study included 26 patients with AT and 41 parents among which 13 patients and 18 parents were evaluated with neurocognitive tests. Clinical and radiological data were reviewed retrospectively. Data were analyzed with descriptive statistics.

    Results: The median ages of patients and parents were 12.5 years (interquartile range [IQR] = 9.5) and 38.0 years (IQR = 12.0), respectively. Median intelligence quotients were 62.0 (IQR = 21.3) and 82.5 (IQR = 16.8), respectively, for patients and parents. Rates of intellectual disability for patients and parents were 100.0% and 83.3%, respectively. Areas of impairment in patients in decreasing order of frequency were motor skills, visual perception/memory, visual-manual coordination, spontaneous/focused and sustained attention (100.0% for each), social judgment, as well as vocabulary and arithmetic skills (75.0% for each). Areas of impairment in unaffected parents in decreasing order of frequency were visual-manual coordination (77.8%), working memory (76.5%), and visual perception and motor skills (66.7% for each).

    Conclusion: Intellectual disabilities, visual-spatial disabilities, and reduced visual-motor coordination seem to be similar in patients with AT and their parents. These results should be replicated with larger samples from multiple centers and may form putative cognitive endophenotypes for the disorder.

    Keywords: Ataxia telangiectasia; Cerebellum; Endophenotype; Neuropsychology.

Page 18 of 21

  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21

Language

Select your language

  • Hindi (India)
  • Hebrew
  • Arabic (اللغة العربية)
  • Turkish (Turkey)
  • 日本語 (Japan)
  • Russian (Russia)
  • Français (France)
  • Deutsch (Deutschland)
  • Español (España)
  • Nederlands (nl-NL)
  • Português Brasileiro (pt-BR)
  • Polski (PL)
  • Italiano (Italia)
  • English (United Kingdom)

Tweets by A_Tinfo

  • Sitemap
Ataxia Telangiectasia
  • Home
  • Bibliography
    • Authors
    • Cells and molecules
    • Clinical
    • Country
    • Diseases
    • Drugs
    • Experimental
    • Journals
    • Methods
    • Year
  • Resources
  • What is A-T?
  • News
  • admin@ataxiatelangiectasia.es